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Old World monkey TRIM5a strongly suppresses human immunodeficiency virus type 1
(HIV-1) replication. A fusion protein comprising cynomolgus macaque (CM) TRIM5 and
cyclophilin A (CM TRIMCyp) also potently suppresses HIV-1 replication. However, CM
TRIMCyp fails to suppress a mutant HIV-1 that encodes a mutant capsid protein containing
a SIVmac239-derived loop between a-helices 4 and 5 (L4/5). There are seven amino acid
differences between L4/5 of HIV-1 and SIVmac239. Here, we investigated the minimum
numbers of amino acid substitutions that would allow HIV-1 to evade CM TRIMCyp-
mediated suppression. We performed random PCR mutagenesis to construct a library of
HIV-1 variants containing mutations in L4/5, and then we recovered replication-competent
viruses from CD4+ MT4 cells that expressed high levels of CM TRIMCyp. CM
TRIMCyp-resistant viruses were obtained after three rounds of selection in MT4 cells
expressing CM TRIMCyp and these were found to contain four amino acid substitutions
(H87R, A88G, P90D and P93A) in L4/5. We then confirmed that these substitutions were
sufficient to confer CM TRIMCyp resistance to HIV-1. In a separate experiment using a
similar method, we obtained novel CM TRIM5a-resistant HIV-1 strains after six rounds of
selection and rescue. Analysis of these mutants revealed that V86A and G116E mutations
in the capsid region conferred partial resistance to CM TRIM5a without substantial fitness
cost when propagated in MT4 cells expressing CM TRIM5a. These results confirmed and
further extended the previous notion that CM TRIMCyp and CM TRIM5a recognize the
HIV-1 capsid in different manners.
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INTRODUCTION
Human immunodeficiency virus type 1 (HIV-1) efficiently
infects humans and chimpanzees, but not Old World
monkeys (OWMs) such as rhesus (Rh) and cynomolgus
(CM) monkeys. In contrast, another lentivirus, simian
immunodeficiency virus isolated from sooty mangabey
(SIVsm), and simian immunodeficiency virus isolated from
African green monkey (AGM) replicate in their natural
hosts (VandeWoude & Apetrei, 2006). The restricted
host range of HIV-1 has greatly hampered its use in
Seven supplementary figures are available with the online
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animal experiments, thus impeding the development of
prophylactic vaccines against HIV-1 infection. In the cells
of OWMs, HIV-1 encounters three main restriction factors:
tripartite motif 5a (TRIM5a) (Stremlau et al., 2004), apo-
lipoprotein B mRNA-editing enzyme-catalytic polypep-
tide-like 3 (APOBEC3) (Sheehy et al., 2002), and bone
marrow stromal antigen 2 (Neil et al., 2008; Van Damme
& Guatelli, 2008). Rh, CM and AGM TRIM5a proteins
potently inhibit HIV-1 infection at the early phase before
reverse transcription (Nakayama & Shioda, 2010).
In these monkey cells, TRIM5a binds to HIV-1 capsid
and promotes its rapid, premature disassembly via ubiqui-
tin-dependent (Diaz-Griffero et al., 2006) and -indepen-
dent (Anderson et al., 2006) processes.
OWMs (macaque monkeys) infected with simian immuno-
deficiency virus isolated from macaque (SIVmac) have
served as important animal models for understanding the
pathogenesis of HIV-1 infection. We previously reported
that HIV-1 replicated efficiently in CM cells when HIV-1
sequences were replaced with the respective SIVmac239
sequences corresponding to all three of the following: the
loop between a-helices 4 and 5 (L4/5) of the capsid protein
(CA); the loop between a-helices 6 and 7 (L6/7) of CA;
and the vif gene (Kuroishi et al., 2009). The resulting
virus (NL-4/5S6/7SvifS) was expected to escape from host
restriction factors CM TRIM5a and APOBEC3G for two
main reasons: first, L4/5 had been reported as a determin-
ant of Rh TRIM5a-mediated restriction (Ylinen et al.,
2005); and second, position 119 or 120 in HIV-2 CA
L6/7 is a determinant of CM TRIM5a-mediated restriction
(Miyamoto et al., 2011; Song et al., 2007). However, the
replicative capability of NL-4/5S6/7SvifS in human cells
was severely impaired. To increase the growth capability
of mutant HIV-1 strains with SIVmac239 sequences,
Nomaguchi et al. (2013b) performed virus adaptation by
long-term culturing in macaque cells, and successfully
obtained adapted viruses with enhanced growth ability.
Sequence analysis revealed that mutations in pol-IN
(N222K and V234I) and env-gp120 (T110I, F247L and
E427K) were responsible for the enhancement of
viral replication. Additionally, a Q112D mutation in CA
helix 6 yielded increased viral growth potential. This
construct was designated MN4Rh-3 (Nomaguchi et al.,
2013b).
The TRIM5 gene-derived allelic variant, TRIMCyp, has
been found in at least three species of OWMs, including
Rh, pig-tailed monkey and CM. CM TRIMCyp suppresses
HIV-1 but not HIV-2 or SIVmac. MN4Rh-3 replicates
robustly in CMs homozygous for TRIMCyp alleles but
not in CMs harbouring only TRIM5a alleles (Saito et al.,
2013). The MN4Rh-3 virus was created by the inclusion
of a net replacement of 11 amino acids in the CA region
(Fig. 1). To define the minimum changes required for
escape from CM TRIMCyp- or CM TRIM5a-mediated
restriction, we performed random PCR-mediated muta-
genesis of the sequence encoding the CypA-binding
region of the HIV-1 capsid.
RESULTS
Known L4/5 point mutations (previously shown to
abolish the interaction between CA and CypA) fail
to confer CM TRIMCyp resistance
As reported previously (Saito et al., 2012), HIV-1 NL4-3
encoding the WT CA (Fig. 1) was completely restricted
by CM TRIMCyp (Figs 2a and S1, available in the online
Supplementary Material). CA/human CypA complex for-
mation is mediated entirely by the contiguous CA loop
sequence P85 to P93 (Fig. 1b), L4/5, which is known to
bind in the active site of CypA (Yoo et al., 1997).
We therefore first tested whether HIV-1 variants encoding
a limited number of mutations in CA L4/5 (mutations that
are known to abolish the interaction between HIV-1 CA
and human CypA) could escape from CM TRIMCyp-
mediated restriction. Previous work (Saito et al., 2012)
showed that replacement of HIV-1 CA with the L4/5 of
SIVmac239 rendered NL-vifS strongly resistant to CM
TRIMCyp (4/5S in Fig. 1b). Our present work confirmed
this result (Fig. 2a). On the other hand, a modification
replacing amino acids 91–93 with a pair of glutamine resi-
dues corresponding to the most prominent difference
between HIV-1 and SIVmac239 L4/5 [(91–93)QQ in
Fig. 1b] was not sufficient to confer CM TRIMCyp resist-
ance (Fig. 2a). The R100S substitution (100S in Fig. 1b),
previously shown to be important for Rh TRIM5a resist-
ance of SIVsm (Kirmaier et al., 2010), also did not yield
CM TRIMCyp resistance (Fig. 2a). The G89-P90 dipeptide
was reported to be the primary CypA recognition motif in
HIV-1 CA (Yoo et al., 1997). However, we found that a
P90A mutation severely impaired viral growth (data not
shown). Previous works also showed that P90AA92E (Qi
et al., 2008), H87Q/I91V (Chatterji et al., 2005) and a
mutation at residue 88 (Price et al., 2009) abolished inter-
action between CA and CypA. However, we found that
amino acid substitutions at these positions (90A92E,
87Q-88P-91V or 88(–), respectively, in Fig. 1b) failed to
confer CM TRIMCyp resistance (Fig. 2a). These results
suggest that binding specificity of HIV-1 CA for the
CypA domain of CM TRIMCyp is similar, but not identi-
cal, to those for the human CypA or for the CypA domain
of owl monkey TRIMCyp.
Selection of a random-mutagenized HIV-1 library
in MT4 cells expressing high levels of CM
TRIMCyp
To define theminimumnumber of amino acid substitutions
of HIV-1 CA sufficient to confer resistance against CM
TRIMCyp, we performed PCR-based random mutagenesis
to construct a large library of HIV-1 variants encoding
mutations in L4/5 (amino acid positions 85 to 93 of CA)
(see Methods). The culture supernatant of 293T cells trans-
fected with 104 clones of this library was collected as a
virus stock. First, we inoculated CD4+ MT4 cells with the
virus stock to amplify replication-competent viruses.
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Fig. 1. Schematic representation of HIV-1 derivatives and relevant CA protein sequences. (a) Bars denote ORFs or long
terminal repeats (LTRs) of HIV-1 NL4-3 or SIVmac239. White and black rectangles denote HIV-1 NL4-3 and SIVmac239
sequences, respectively. (b) Alignments of partial amino acid sequences of capsid proteins of HIV-1 mutants and
SIVmac239. The names of viruses previously used in the referenced reports, are shown in parentheses. aNomaguchi et al.
(2013b) and bKuroishi et al. (2010). A dash denotes the amino acid residue identical to that of NL4-3. An asterisk denotes
an amino acid residue different from that of NL4-3. The box indicates the amino acid residues in L4/5 and L6/7. The positions
of G116E and Q112D substitutions are indicated. Symbols ++,+ and – denote more than 100-fold, 3- to 100-fold and
less than 3-fold suppression of viral growth by CM TRIMCyp or TRIM5a compared with viral growth in the presence of CM-
SPRY(–) TRIM5a on day 6. ND, Not determined; (+), virus suppression with poor virus growth even in the absence of func-
tional TRIM5a.




































































































Fig. 2. Growth of HIV-1 mutants in MT4 cells expressing CM-SPRY (–) TRIM5a, CM TRIMCyp or CM TRIM5a. (a) MT4 cells
expressing CM-SPRY (–) TRIM5a (black bars) or CM TRIMCyp (grey bars) were superinfected with the indicated HIV-1
derivatives. (b, c) MT4 cells expressing CM-SPRY (–) TRIM5a (black bars), CM TRIMCyp (grey bars) or CM TRIM5a (white
bars) were superinfected with the indicated HIV-1 derivatives. Culture supernatants were assayed at day 6 and the levels of
p24 antigen were plotted. Error bars show actual fluctuations of p24 in duplicate samples. The results shown are representa-
tive of at least two independent experiments.
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We then applied a functional screen to isolate adapted
virus in MT4 cells expressing CM TRIMCyp. The viruses
were rescued by adding fresh MT4 cells without CM
TRIMCyp. The selection process was repeated twice more,
such that we characterized those viruses obtained after
three rounds of selection for CM TRIMCyp resistance
(Fig. S2a). Notably, when we subjected parental cloned
NL-vifS virus to adaptation in CM TRIMCyp-expressing
cells, no virus was recovered from the third round of
selection, despite the addition of fresh MT4 cells, in a total
interval of 2 months (data not shown).
Sequence analysis of the CA-coding region of the provirus
recovered in MT4 cells expressing CM-TRIMCyp revealed
the presence of H87R, A88G, P90D and P93A mutations.
We obtained a similar but distinct combination of
mutations (H87R, G89E, A92T and P93T) from an
independent experiment selecting for adaptation to CM
TRIMCyp.
H87R/A88G/P90D/P93A and H87R/G89E/A92T/
P93T mutations confer complete resistance
against CM TRIMCyp
To examine the effect of mutations found in adapted
viruses, the respective four mutations in L4/5 were intro-
duced into the parental NL-vifS molecular clone, yielding
clones RGDA (encoding H87R, A88G, P90D and P93A)
and RETT (encoding H87R, G89E, A92T and P93T).
As shown in Figs 2(b) and S3, both viruses were (like
4/5S) strongly resistant to CM TRIMCyp restriction,
whereas they were completely sensitive to CM TRIM5a.
The growth capability of these viruses was analysed in the
absence of TRIM5a-mediated restriction by using MT4
cells infected with a Sendai virus (SeV) encoding a TRIM5
protein lacking the PRYSPRY domain. The results revealed
that RGDA grew to higher titres than RETT (Fig. 2b). There-
fore we selected H87R/A88G/P90D/P93A mutations for
further evaluation.
We had previously succeeded in rescuing the impaired
replicative capability of NL-4/5S6/7SvifS; in that work, we
reported that the G116E mutation improved the virus’s
replicative capability (Kuroishi et al., 2010). Notably,
HIV-1 with the G116E mutation became partially resistant
to CM TRIM5a-mediated restriction (Kuroishi et al.,
2010). Therefore, we introduced the G116E mutation
into RGDA and tested the resulting clone (designated
RGDA116E) for resistance against CM TRIM5a and CM
TRIMCyp. We found that inclusion of the additional
G116E mutation did not affect virus growth. As expected,
RGDA116E was able to grow in MT4 cells expressing CM
TRIM5a, confirming that the G116E substitution is
important for resistance to CM TRIM5a. The inclusion
of the 6/7S mutation in RGDA was detrimental to viral
growth; in contrast, inclusion of both the 6/7S and
G116E mutations in RGDA was favourable for viral
growth (Fig. 2b). These findings are consistent with our
previous results (Kuroishi et al., 2010).
Finally, we introduced the Q112D mutation (previously
reported as Q110D mutation in MN4Rh-3; Nomaguchi
et al., 2013b) (Fig. 1), into RGDA to generate RGDA112D.
Similar to the reported data for MN4Rh-3 (Nomaguchi
et al., 2013b), the combination of RGDA, L6/7S and Q112D
mutations was acceptable for virus growth (Fig. 2b).
V86A/G116E mutations confer partial resistance
against CM-TRIM5a
Next, we attempted to obtain CM TRIM5a-resistant
viruses from the same library as described above.
We inoculated amplified replication-competent virus to
MT4 cells infected with recombinant SeV encoding CM
TRIM5a. The viruses were rescued by adding fresh MT4
cells. A total of six rounds of selection and rescue were
required to obtain CM TRIM5a-resistant virus; the seventh
round of selection confirmed the resistance to CM TRIM5a
(Fig. S2b). Sequence analysis of the CA-encoding region of
the provirus DNA revealed the presence of V86A and
G116E mutations. As noted above, we have previously
reported that HIV-1 harbouring a G116E mutation was
partially resistant to CM TRIM5a-mediated restriction
(Kuroishi et al., 2010). The V86A and G116E mutations
were introduced into the parental NL-vifS molecular
clone, yielding strain 86A116E. When propagated in MT4
cells expressing CM TRIM5a, 86A116E grew to higher
p24 levels than obtained with 116E (Figs 2c and S4).
These results indicate that the V86A mutation potentiated
the CM TRIM5a resistance of the strain carrying the G116E
mutation alone, although these double-mutant viruses
showed only partial resistance against CM TRIM5a.
Since position 120 in L6/7 of HIV-2 is a determinant of CM
TRIM5a sensitivity (Song et al., 2007), we replaced the
region encoding L6/7 of 86A116E with that of SIVmac239,
generating 86A116E6/7S. However, 86A116E6/7S did not
grow in the presence of CM TRIM5a, presumably due to
a detrimental effect of the replacement of L6/7 with that
of SIVmac239. We also constructed another two strains
(designated 86M116E and 86E116E) encoding distinct
substitutions at V86. A previous study had shown that
V86M CA allows HIV-1 to grow in HeLa-CD4 cells
expressing Rh TRIM5a (Pacheco et al., 2010); separate
work revealed that the V86E mutant exhibits decreased sen-
sitivity to restriction by the Rh TRIM5a (Soll et al., 2013).
When we compared the growth of all three V86 mutants
in the presence of CM TRIM5a, 86A116E grew to higher
titres in the presence of CM TRIM5a than 86E116E
(Fig. 2c). On the other hand, 86M116E exhibited growth
similar to that of 86A116E in the presence of CM TRIM5a
(Fig. 2c).
To confirm fitness of all the mutant viruses, we used un-
modifiedMT4 cells. Except for viruses carrying 112D substi-
tution, mutant viruses showed similar growth capability in
unmodified MT4 cells to those described above (Fig. S5).
In contrast, viruses with 112D showed slightly reduced
growth capability in unmodified MT4 cells (Fig. S5).
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Viral resistance to CM TRIMCyp- and TRIM5a-
mediated restriction in a single-round infection
assay
The assay system described in Fig. 2 investigated the effect
of CM TRIMCyp and CM TRIM5a on the multi-step
growth of the viruses. Since TRIM5a restricts HIV-1 infec-
tion at the early steps of viral infection, we performed a
single-round infection assay by using vesicular stomatis
virus glycoprotein (VSV-G)-pseudotyped virus with luci-
ferase gene as a reporter in the nef gene. Prior to proceed-
ing with this experiment, we measured reverse transcriptase
(RT) activity of each mutant virus to check if mutations
hampered the sensitivity of p24 ELISA; we detected no dis-
crepancy between RT and p24 activities among the mutants
(Fig. S6). The replacement of L4/5 with that of SIVmac239
and RGDA sequences impaired the infectivity in compari-
son with that of the WT (Fig. 3). The viruses carrying
sequences encoding the CA of 4/5S, 4/5S112D6/7S,
RGDA or RGDA112D showed high degrees of resistance
to CM TRIMCyp (Fig. 3).
On the other hand, the 86A116E double mutant exhibited
only a minor change in infectivity. The mutants carrying
sequences encoding the CA of 4/5S, 4/5S112D6/7S,
RGDA or RGDA112D showed almost no resistance to
CM TRIM5a compared with 86A116E or 86M116E
mutants, results that were in good agreement with the
growth capabilities in the presence of CM TRIM5a in
multi-step experiments (Fig. 2b, c). The virus carrying
the G116E mutation alone showed very slight resistance
to CM TRIM5a in comparison with virus encoding the
WT capsid. The viruses carrying 86A116E or 86M116E
mutations showed partial resistance to CM TRIM5a
(Fig. 3), confirming that CA position 86 is important for
resistance to CM TRIM5a-mediated restriction.
Binding of HIV-1 CA to CM TRIMCyp in virion
incorporation assay
To measure the binding capability of HIV-1 CA to the
CypA-like domain of CM TRIMCyp, we performed
virion incorporation assays. For these assays, 293T cells
were co-transfected with a recombinant plasmid encoding
the CypA-like domain of CM TRIMCyp fused with the
HA tag together with NL-Nh derivatives of viruses encod-
ing WT or mutant (90A92E, RGDA, RETT, 86A116E or
4/5S) capsids. Western blot analysis using antibody against
the HA tag showed that HIV-1 virion particles encoding
RGDA or RETT mutant capsids showed almost no incor-
poration of the HA-tagged CypA-like domain of CM
TRIMCyp compared with that of the WT and 86A116E
(Fig. 4a), although the transfected cells expressed compar-
able amounts of HA-tagged CypA proteins. These results
suggest that capsid with the RGDA or RETT mutations
has decreased binding affinity for CM TRIMCyp, and
that this loss of affinity for the CypA-like domain of CM
TRIMCyp is critical for escape from restriction by CM
TRIMCyp.
When we performed an equivalent experiment using 293T
cells that had been co-transfected with recombinant plas-
mid encoding authentic human CypA, the 90A92E and
4/5S capsid mutants showed very low incorporation of
authentic CypA (Fig. 4b). In contrast, virions with the
90A92E mutation incorporated large amounts of the
CypA-like domain of CM TRIMCyp, whereas virions
with the 4/5S mutation incorporated very small amounts
of the CypA-like domain of CM TRIMCyp. These results
are in good agreement with the observation that 4/5S
(and not 90A92E) grew in the presence of CM TRIMCyp
(Fig. 2a).
Molecular modelling of the CA N-terminal domain
(NTD) of HIV-1 variants
To obtain structural insights into viral resistance to CM
TRIMCyp and CM TRIM5a, we constructed three-dimen-
sional models of the CA NTD of four HIV-1 strains with
different sensitivities to the antivirals via different sets of
amino acid residues on the CA NDT. The modelling
revealed that the CA substitutions for the CM TRIMCyp
and CM TRIM5a resistance are distributed differently on
the NTD: the former are uniformly arranged along the
exposed surface on L4/5, whereas the latter are positioned
on L4/5 near helix 4 and at helix 6 (Fig. 5a). These results
suggest that CM TRIMCyp and CM TRIM5a target dis-
tinct surfaces in the CA NTD of HIV-1: L4/5 is critical
for CM TRIMCyp-mediated antiviral activity, while
other regions containing L4/5 and helix 6 are involved in
CM TRIM5a-mediated antiviral activity. These results
are consistent with our previous finding of differential
antiviral roles of CM TRIMCyp and CM TRIM5a in
HIV-1 infection (Saito et al., 2013). In addition, the pres-
ent results also agree well with our previous findings indi-
cating the critical roles of amino acid residues in L4/5 and
helix 6 in CM TRIM5a resistance (Nomaguchi et al.,
2013a, 2014). The present study further showed that the
main chain folds of the CA NTD of the HIV-1 variants
are indistinguishable, although minor changes were
noticed in the L4/5 conformation of the CM TRIMCyp-
resistant mutants (Fig. 5b). The results suggest that
changes in physico-chemical features on the binding
surface, rather than surface conformation, are critical for
the phenotypic modifications in this study. Such changes
might cause alterations in electrostatic attraction (H87R,
G89E, P90D and G116E), hydrophobic attraction
(V86A), and/or loop dynamics (P93T/A and A88G) for
ligand recognition/binding; further study is necessary to
address these issues.
Replication of HIV-1 derivatives in monkey
peripheral blood mononuclear cells (PBMCs)
Nomaguchi et al. (2013b) reported that several mutations
at defined sites in the Pol-integrase and/or the Env-gp120
(MN4Rh-3) enhanced growth potential in macaque cells.
Therefore, we transferred the CA-encoding regions of
T. Sultana and others
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Fig. 3. Viral infectivity (a) and sensitivity to CM TRIMCyp (b) and CM TRIM5a (c) in a single-round infection assay. MT4 cells
expressing CM TRIM5Cyp, CM TRIM5a or CM-SPRY (–) TRIM5a were superinfected with VSV-G-pseudotyped HIV-1
derivatives with luciferase reporter gene. The infectivity of a clone was measured by dividing the luciferase activity of that
clone in the presence of CM-SPRY (–) TRIM5a by the luciferase activity of the WT NL4-3-Luc-R-E in the presence of
CM-SPRY (–) TRIM5a. To quantify the resistance to CM TRIMCyp or CM TRIM5a of a clone, luciferase activity of that clone
in the presence of CM TRIMCyp or CM TRIM5a, respectively, was divided by the luciferase activity of that clone in the
presence of CM-SPRY (–) TRIM5a. The results shown are representative of at least three independent experiments.
Error bars show SD among triplicate samples.
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RGDA112D and 86A116E to the MN4Rh-3 backbone,
yielding constructs designated RGDA112D-Rh and
86A116E-Rh, respectively. We then confirmed the com-
plete resistance to CM TRIMCyp of MN4Rh-3 and
RGDA112D-Rh and partial resistance to CM TRIM5a
of 86A116E-Rh in MT4 cells expressing CM TRIMCyp
or TRIM5a (Fig. 6a).
To infer the growth capability of HIV-1 derivatives in
monkey, CD8-depleted PBMCs isolated from TRIMCyp
or TRIM5a homozygous CMs were infected with HIV-1
derivatives in vitro. As shown in Fig. 6(b), SIVmac239
replicated very rapidly in PBMCs regardless of the host
genotype. MN4Rh-3 and RGDA112D-Rh showed similar
growth kinetics in PBMCs from a CM TRIMCyp homozy-
gote, but did not grow in PBMCs from a CM TRIM5a
homozygote (Fig. 6b). We evaluated PBMCs from two
additional CM TRIMCyp homozygotes and found that
PBMCs from all these CM TRIMCyp homozygotes also
supported growth of RGDA112D-Rh (Fig. S7). On the
other hand, 86A116E-Rh showed growth in PBMCs from
a CM TRIM5a homozygote, although the peak titre of
this strain was lower than that of SIVmac239 (Fig. 6b).
To our knowledge, this result represents the first report
of an HIV-1 derivative that can replicate in the PBMCs
of a CM TRIM5a homozygote. We evaluated PBMCs
from seven additional CM TRIM5a homozygotes and






































Fig. 4. Characterization by virion incorporation assay of the ability of different capsid mutants of HIV-1 to bind to the CypA-
like domain of CM TRIMCyp. 293T cells were co-transfected with NL-Nh (WT) or capsid mutations 90A92E, RGDA, RETT,
86A116E and 4/5S, together with pCEP4 vector encoding the HA-tagged CypA-like domain of CM TRIMCyp (a) or with
pCEP4 vector encoding HA-tagged authentic human CypA (b). After normalization for p24 amount, virions were subjected to
SDS-PAGE followed by Western blot analysis using anti-HA and anti-p24 antibodies. The cell lysate of transfected 293T
cells served as a control for the transfection. This result is representative of at least two independent experiments.
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TRIM5a homozygotes supported growth of 86A116E-Rh
(Fig. S7). These results are consistent with the results
obtained in MT4 cells expressing CM TRIMCyp and
TRIM5a via recombinant SeV, as shown in Fig. 2(b, c),
although the reason why PBMCs from five out of eight CM
TRIM5a homozygotes failed to support growth of
86A116E-Rh is not clear. As expected, while RGDA112D
grew in MT4 cells expressing CM TRIMCyp (Fig. 2b), this
strain was not able to grow in PBMCs from a CM TRIMCyp
homozygote. Similarly, 86A116E also did not grow in
PBMCs from a CM TRIM5a homozygote, although this
strain provided resistance against CM TRIM5a in MT4
cells (Fig. 2c).
DISCUSSION
Random mutagenesis of HIV-1 CA L4/5-encoding
sequences, followed by selection by CM TRIMCyp,
permitted the identification of novel mutations
(H87R/A88G/P90D/P93A and H87R/G89E/A92T/P93T)
in L4/5 that provided strong resistance to CM TRIMCyp.
We also found that the V86AG116E double mutation con-
ferred partial resistance to CM TRIM5a without apparent
fitness cost. Position 86 is located at the N-terminal end
of L4/5, while the four-mutation combinations (RGDA
and RETT) are scattered across the entire L4/5. These
results indicate that CM TRIMCyp and CM TRIM5a
recognize the HIV-1 capsid in different manners.
In our initial attempt at characterizing the CA–CypA inter-
action, we tested several HIV-1 derivatives harbouring
mutations known to impair CypA binding (Li et al., 2009;
Price et al., 2009). However, with the exception 4/5S,
none of the selected mutant viruses exhibited replication
in the presence of CM TRIMCyp. By using the virion incor-
poration assay, we found that the capsids with the novel
mutations (RGDA or RETT) failed to incorporate
WT RETT
RGDA















Fig. 5. Structural models for CA NTDs of HIV-1 NL4-3 derivatives. Structural models were constructed by homology-model-
ling using ‘MOE-Align’ and ‘MOE-Homology’ in MOE. The crystal structure of the HIV-1 CA NTD at a resolution of 2.00 Å
(PDB code: 1M9C) was used as the modelling template. (a) CA NTD structural models for NL4-3 (WT, grey) and its deriva-
tives (white) containing amino acid substitutions for CM TRIMCyp resistance (RETT and RGDA) and for CM TRIM5a partial
resistance (86A116E) are shown. (b) Superposed structures of CA NTD of NL4-3 and its derivatives.






















1 3 6 
Days after infection
Days after infection































































Fig. 6. Replication capabilities of HIV-1 derivatives in CD8-depleted PBMCs from CM. (a) MT4 cells expressing CM TRIM-
Cyp (&), CM TRIM5a (D), CM-SPRY or (–) TRIM5a (#) were superinfected with the indicated HIV-1 derivatives. The results
shown are representative of at least two independent experiments. Error bars, that are hidden behind the symbols due to their
small values, show actual fluctuations between measurements of p24 in duplicate samples. (b) CD8-depleted PBMCs from
CM TRIMCyp homozygote or CM TRIM5a homozygote were infected with RGDA112D, RGDA112D-Rh, 86A116E or
86A116E-Rh. MN4Rh-3 and SIVmac239 served as controls.
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the CypA-like domain of CM TRIMCyp; in contrast, HIV-1
virions with 90A92E mutations still incorporated the
CypA-like domain of CM TRIMCyp. We therefore con-
clude that the loss of binding affinity of capsid to the
CypA domain of CM TRIMCyp confers resistance to
TRIMCyp-mediated restriction. It would be interesting to
see how these CA mutants behave in other contexts, such
as stimulation of interferon responses (Rasaiyaah et al.,
2013) and interaction with NUP358 (Schaller et al., 2011).
Previous studies showed the importance of capsid binding
of authentic CypA for HIV-1 replication in human cells
(Braaten et al., 1996). In the present study, we confirmed
the importance of this interaction, since all the mutant
viruses that are known to lack CypA incorporation
showed impaired growth (as shown in Figs 2 and S1).
The monkey-tropic HIV-1 MN4Rh-3 strain also showed
impaired growth in human cells compared with NL-vifS,
a strain that encodes WT capsid. We therefore tried to
create (using random mutagenesis) an HIV-1 derivative
that can replicate as well as the WT but completely lacks
binding affinity for CM TRIMCyp. Contrary to our expec-
tation, the isolated viruses in two independent experiments
failed to retain the full capacity for replication, although
these viruses completely overcame TRIMCyp-mediated
restriction. These results suggest a critical role for CypA
binding (and/or a role for the CypA-binding loop) in the
context of infection by HIV-1 but not by SIVmac.
It is noteworthy that the G116E substitution was obtained
repeatedly in the experiments described here. We pre-
viously showed that position 116 is located in the sixth
helix, near L4/5 and L6/7, where this residue is apparently
exposed to the protein surface. An amino acid substitution
at position 116 is expected to cause a change in the struc-
ture of the protein surface, given the chemical dissimilarity
between G (which has no side chain) and E (which has a
long, negatively charged side chain) (Kuroishi et al.,
2010). Repeated isolation of this lesion also suggests that
this site on the CA tolerates changes and is not essential
for viral replication.
The importance of mutation in position 86 was emphasized
by the single-round luciferase infection assay. The G116E
mutation showed a higher degree of resistance against CM
TRIM5a when combined with V86A or V86M (Fig. 3).
It was previously reported that V86M CA allows HIV-1 to
escape from Rh (Pacheco et al., 2010) and mutant human
TRIM5a (Veillette et al., 2013). On the other hand, virus har-
bouring only the V86E mutation exhibits decreased Rh
TRIM5a sensitivity (Soll et al., 2013). In the present study,
however, we recovered only the V86A mutant, and not a
V86M or V86E mutant. We hypothesize that further
rounds of selection may yield V86M, since only one nucleo-
tide substitution is required to convert V to M; we do not
expect to recover V86E, given that the V86E mutation
showed a detrimental effect on viral growth (Fig. S4).
RGDA112D-Rh, the novel HIV-1 derivative described in
this work, showed growth capability similar to that of the
previous molecular clone MN4Rh-3 in CD8-depleted
CM PBMCs derived from a TRIMCyp homozygote.
RGDA112D-Rh bears only five amino acid substitutions
in the CA; in contrast, MN4Rh-3 bears 11 substitutions
compared with the WT (Fig. 1). We also note here that
this work represents the first report (to our knowledge)
of an HIV-1 derivative that can replicate in the PBMCs
of a CM TRIM5a homozygote. Though the 86A116E
mutant showed growth kinetics superior to the other
mutants, further improvement will be necessary to obtain
an appreciable infection in CM. Random mutagenesis in
the whole N-terminal region of the CA may be required,
since the region that interacts with TRIM5a is larger than
that interacting with TRIMCyp. In the present study, we
focused only on the CA-encoding sequence for random
mutagenesis and adaptation; other sequences in pol, env
or other loci were not mutagenized. It also would be inter-
esting to see whether extended intervals of adaptation
would yield additional or distinct mutations for escaping
the restriction pressure of CM TRIM5a or for compensat-
ing for the impaired growth in the presence of CM
TRIMCyp. Additionally, Rh and CM TRIM5as exhibit dis-
tinct antiviral activities (Kono et al., 2010); growth of both
RGDA and 86A116E were completely suppressed in the
presence of Rh TRIM5a. We are currently attempting to
recover virus from cells overexpressing Rh TRIM5a.
We evaluatedPBMCs fromthreeCMTRIMCyphomozygotes
and found that PBMCs from all three CM TRIMCyp homo-
zygotes supported growth of RGDA112D-Rh (Fig. S7).
On the other hand, PBMCs from five out of eight
CM TRIM5a homozygotes failed to support growth of
86A116E-Rh (Fig. S7). Since SIVmac239 replicated well in
all those PBMCs, these results indicated the presence of
inter-individual differences in susceptibility to 86A116E-Rh
infection among CM TRIM5a homozygotes. It is possible
that other host factor(s) that affect HIV-1 replication in CM
are involved in this difference. Since RGDA112D-Rh was
strongly resistant against CM TRIMCyp, like MN4Rh-3,
effects of the other host factor(s) may be neglected. On the
other hand, 86A116E-Rh could only partially escape from
CM TRIM5a, and effects of the other host factor(s) may
become more prominent. Further study is necessary to
identify such host factor(s).
METHODS
Cell culture. The human kidney adherent 293T cell line was cultured
in Dulbecco’s modified Eagle’s medium supplemented with 10 %
heat-inactivated FBS at 37 uC with 5 % CO2. MT4, a human CD4
+T
cell line immortalized by human T cell leukemia virus type-1
(Akagi et al., 1985), was maintained in RPMI 1640 medium
containing 10 % FBS.
Viruses. NL-vifS possesses the entire vif gene of SIVmac239 in the
HIV-1 NL4-3 background (NL-SVR in Kamada et al., 2006) (WT).
NL-4/5S6/7SvifS encodes CA with the SIVmac239-derived L4/5 and
L6/7 in the NL-vifS background (Kuroishi et al., 2009) (4/5S6/7S).
NL-G116EvifS encodes a G-to-E substitution at position 116 of
the CA in the NL-vifS background (Kuroishi et al., 2010) (116E).
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The MN4Rh-3 was reported previously (Nomaguchi et al., 2013b).
Amino acid substitutions in the NL-vifS CA shown in Fig. 1 were
introduced by site-directed mutagenesis with the PCR-mediated
overlap primer extension method. The sequence authenticities of all
clones were confirmed by sequencing of the CA-encoding region. Virus
stocks were prepared by transfection of 293T cells with HIV-1 NL-vifS
and its derivatives using the polyethylenimine (molecular mass 25 000;
Polysciences) method. Viral titres were measured using the p24
RetroTek antigen ELISA kit (ZeptoMetrix). Viral RT was quantified
with theReverseTranscriptaseAssay, colorimetric (RocheDiagnostics).
Luciferase-expressing viruses. For the 4/5S, MN4Rh-3,
RGDA112D, 86A116E, 86M116E and 116E constructs, the respective
BssHII–Apa I fragment [which encodes matrix (MA) and CA] was
subcloned into NL4-3-Luc-R-E-(NIH AIDS Research and Reference
Reagent Program) to generate the corresponding luciferase reporter
vector. To recover the VSV-G-pseudotyped luciferase-expressing
viruses, 293T cells were co-transfected with 12 mg reporter plasmid
and 5 mg VSV-G-expressing plasmid (pMD2G) (Dull et al., 1998).
Recombinant Sendai viruses. SeVs encoding CM TRIMCyp, CM
TRIM5a and CM TRIM5a without the SPRY domain [CM-SPRY
(2)] were described previously (Kono et al., 2008; Nakayama et al.,
2005; Song et al., 2007).
Library construction. PCR with degenerate primers was performed
using 1 mg NL-vifS plasmid, Ex Taq polymerase (TaKaRa) and
(separately) the following primer pairs: (1) M661F (59-gccagagga-
gatctctcgacgcagg-39) and Pst-R (59-caatctatcccattctgcagcttc-39) or (2)
NL43-ODN (59-tgggatagattgcatCCaGTgCAtGCaGGgCCtATtGCaCC
aggccagatgagagaa-39) and 2011R (taggggccctgcaatttttggctatgtgcccttc-39).
The NL43-ODN primer was designed to introduce random mutations
in the L4/5-encoding region of NL4-3, corresponding to amino acid
positions 85 to 93 of CA. Specifically, the primer was synthesized so as
to introduce random mutations at the nucleotides shown in capital
letters in the sequence above. Synthesis was performed so that (at each
of those positions) 91 % of the oligonucleotides would have the
correct residue, while 3 % would have one of the three other residues.
The mutations were confined to the first and second residues of the
respective codons in order to minimize the occurrence of silent
mutations. The nucleotides underlined in the Pst-R and NL43-ODN
sequences are complementary. PCR products obtained from PCR
reactions (1) and (2) above were mixed and used as templates for a
second round of PCR with the M661F and 2011R primer pair. The
resulting PCR products were double-digested with BssHII and Apa I,
and then ligated into NL-vifS vector that had been subjected to
double-digestion with the same enzymes. Recombinant plasmids were
recovered by transformation of Escherichia coli JM109, yielding
1|104 colonies across a total of 12 dishes. We randomly picked 20 of
the recombinant colonies and obtained DNA sequences for the
CA-encoding region of each clone. We found that approximately
two-thirds of the clones harboured mutations in the L4/5-encoding
sequences. Among these clones, the number of mutated nucleotides
varied from one to six, with a mean of three mutations each. The
contents of each plate of the primary library were (separately) pooled
and prepped. Twenty micrograms of the random-mutated plasmid
library purified from each E. coli plate was transfected into 293T cells
in 10 cm dishes using polyethylenimine. Three days after transfection,
culture supernatants of the 12 plates were collected separately and
assessed by ELISA for p24 antigen.
Selection of a random-mutagenized HIV-1 library in MT4 cells
expressing CM TRIMCyp or CM TRIM5a. MT4 cells (1.2|106)
were infected with SeV encoding CM-SPRY (2) TRIM5a at an m.o.i.
of 10 p.f.u. per cell and incubated at 37 uC for 9 h. Cells were divided
into 12 tubes, and each tube was then infected with a titre of
each library equivalent to 100 ng p24. After incubating for 2 h, the
cells were washed in 10 % FCS-supplemented RPMI 1640, then
resuspended in 10 ml of the same medium and incubated at 37 uC for
4 days. The resulting culture supernatants (the replication-competent
virus stocks) were harvested and stored at280 uC. For the selection of
the CM TRIMCyp- or CM TRIM5a-resistant virus, MT4 cells
(1|106) were infected with SeV encoding CM TRIM5Cyp or CM
TRIM5a, and then infected with a titre of each virus stock equivalent
to 100 ng p24. Every 3 or 4 days, an aliquot (5 ml) of culture super-
natant was collected and replaced with fresh medium. After 2–3 weeks,
fresh (not SeV-infected) MT4 cells were added to rescue any existing
resistant virus. When culture supernatant had accumulated p24 anti-
gen to levels w100 ng ml21, we prepared MT4 cells newly infected
with recombinant SeV and inoculated these cells with a titre of
supernatant equivalent to 100 ng p24 for the next round of selection.
TRIM5 resistance assay. MT4 cells (105) were first infected with
SeV encoding CM TRIM5Cyp, CM TRIM5a, or CM-SPRY (2)
TRIM5a at an m.o.i. of 10 p.f.u. per cell and incubated at 37 uC for
9 h. Cells were then superinfected with a titre corresponding to 20 ng
p24 of HIV-1 derivatives. The culture supernatants were collected
periodically, and the levels of p24 were measured with an ELISA kit.
Single-round infection assay. MT4 cells were infected with SeV
encoding CM TRIM5Cyp, CM TRIM5a or CM-SPRY (2) TRIM5a as
described above, and superinfected with VSV-G-pseudotyped HIV-1
clones harbouring a luciferase reporter gene. Two days after infection,
the luciferase activities in infected cells were measured by Bright-Glo
Luciferase Assay (Promega) according to the manufacturer’s
instructions. The infectivity of a clone was measured by dividing the
luciferase activity of that clone in the presence of CM-SPRY (2)
TRIM5a by the luciferase activity of WT NL4-3-Luc-R-E in the pre-
sence of CM-SPRY (2) TRIM5a. To ascertain the resistance to CM
TRIMCyp or CM TRIM5a of a clone, luciferase activity of that clone
in the presence of CM TRIMCyp or CM TRIM5a, respectively, was
divided by the luciferase activity of that clone in the presence of CM-
SPRY (2) TRIM5a.
Virion incorporation assay and Western blotting. NL-Nh is a
mutant of the NL4-3 proviral clone in which an Nhe I restriction
enzyme cleavage site has been blunted and religated, introducing a
frameshift mutation in the env gene (Sakuragi et al., 2003). The
BssHII–Apa I fragments of capsid-encoding regions of 90A92E,
RGDA, RETT, 86A116E and 4/5S were subcloned (separately) into the
NL-Nh plasmid. Sequences encoding the CypA-like domain of CM
TRIMCyp and authentic human CypA were PCR-amplified and
cloned (separately) into the pCEP4 mammalian expression vector
(Invitrogen). Then 293T cells were co-transfected with plasmids
encoding the HA-tagged CypA region of CM TRIMCyp and the
aforementioned HIV-1 NL-Nh derivatives. The resulting supernatants
were layered onto a 2 ml cushion of 20 % sucrose in PBS and cen-
trifuged at 35 000 r.p.m. for 2 h in a Beckman SW41 rotor to purify
the virions. After centrifugation, the virion pellets were resuspended
in PBS, and p24 antigen concentrations were measured by ELISA.
A titre corresponding to 50 ng p24 of the respective HIV-1 derivative
was subjected to SDS-PAGE. Proteins in the gel were then transferred
electrically to a PVDF membrane (Immobilon; Millipore). Blots were
blocked and probed with anti-HA high-affinity rat monoclonal
antibody (Roche Diagnostics) or with anti-p24 antibody (Abcam)
overnight at 4 uC. Blots then were incubated with peroxidase-con-
jugated anti-rat IgG antibody (American Qualex) or anti-mouse IgG
antibody (KPL), respectively, and bound antibodies were visualized
with a Chemi Lumi-One L chemiluminescent kit (Nacalai Tesque).
Equivalent experiments were performed with a plasmid encoding
HA-tagged authentic human CypA.
Computational modelling of mutant HIV-1 CA. Molecular models
of NTD of HIV-1 CA mutants were constructed by homology
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modelling using ‘MOE-Align’ and ‘MOE-Homology’ in the Mol-
ecular Operating Environment (MOE) (Chemical Computing Group)
and refined as described previously for the modelling of HIV-1 CA
NTD (Nomaguchi et al., 2013a, b, 2014). The crystal structure of the
HIV-1 CA NTD at a resolution of 2.00 Å [Protein Data Bank (PDB)
accession number 1M9C (Howard et al., 2003)] was used as the
modelling template. Superimpositions of the structures were done
using the Protein Superpose module in MOE.
Propagation of CD8-depleted CM PBMCs and viral infection.
The TRIM5 genotypes of individual monkeys were determined pre-
viously (Saito et al., 2012). PBMCs from both CM TRIMCyp and CM
TRIM5a homozygotes were suspended in RPMI 1640 medium sup-
plemented with 10 % FBS, and the CD8+ cells were removed with a
magnetic bead system (Miltenyi Biotec). The CD8-depleted PBMCs
were first stimulated for 2 days with 1 mg ml21 PHA-L (Sigma) and
then with human IL2 (100 U ml21) for an additional 2 days.
An aliquot of 3|105 cells was then inoculated with a titre of virus
equivalent to 60 ng p24 (for MN4Rh-3, RGDA112D, RGDA112D-Rh
or 86A116E) or with a titre of virus equivalent to 60 ng p27 (for
SIVmac239) and incubated at 37 uC in medium containing 100 U
ml21 human IL2. The culture supernatants were collected periodically,
and the levels of viral antigen were measured using the ELISA kit.
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